These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444 [TBL] [Abstract][Full Text] [Related]
26. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Catapano AL Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768 [TBL] [Abstract][Full Text] [Related]
28. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered? Jacobson TA Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219 [TBL] [Abstract][Full Text] [Related]
29. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Hou R; Goldberg AC Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513 [TBL] [Abstract][Full Text] [Related]
30. Statins and myotoxicity: a therapeutic limitation. Tiwari A; Bansal V; Chugh A; Mookhtiar K Expert Opin Drug Saf; 2006 Sep; 5(5):651-66. PubMed ID: 16907655 [TBL] [Abstract][Full Text] [Related]
31. HDL-C: role as a risk modifier. Barter P Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280 [TBL] [Abstract][Full Text] [Related]
32. Understanding cholesterol: high is bad but too low may also be risky -- is low cholesterol associated with cancer? Simko V; Ginter E Bratisl Lek Listy; 2014; 115(2):59-65. PubMed ID: 24601696 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316 [TBL] [Abstract][Full Text] [Related]
34. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
35. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
36. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations. Adhyaru BB; Jacobson TA Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517 [TBL] [Abstract][Full Text] [Related]
37. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Conde K; Pineda G; Newton RS; Fernandez ML Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079 [TBL] [Abstract][Full Text] [Related]
38. [Statins and anesthesia: dilemma or obviousness? Is there still room for withdrawal of chronic statin therapy before surgery?]. Pichon G; Deflandre E; Opsomer O; Pichon L; Jaucot J Rev Med Liege; 2012 Feb; 67(2):69-74. PubMed ID: 22482235 [TBL] [Abstract][Full Text] [Related]